• Other
  • Exited

Selexys Pharmaceuticals is committed to advancing the treatment of inflammatory diseases. Selexys lead candidate, SelG1, is an anti-P-selectin monoclonal antibody that prevents various cells in the bloodstream from sticking together. Selexys is currently conducting a Phase 2 clinical trial for SelG1, in patients with sickle cell disease. The Phase 2 trial (called the SUSTAIN study) will assess drug safety and test whether inhibition of these cell-cell interactions with SelG1 will prevent small blood vessels from becoming blocked and therefore reduce the occurrence and severity of pain crises.